A new review published in Current Pharmaceutical Analysis provides an in-depth look at the latest analytical techniques used for impurity profiling and forced degradation studies of Angiotensin (AT1) ...

The data from 2019 to 2023 show rapid uptake of the drugs alongside wide patient- and practice-level variations.